PL1969118T3 - Wyizolowane komórki macierzyste wątroby - Google Patents

Wyizolowane komórki macierzyste wątroby

Info

Publication number
PL1969118T3
PL1969118T3 PL06819033T PL06819033T PL1969118T3 PL 1969118 T3 PL1969118 T3 PL 1969118T3 PL 06819033 T PL06819033 T PL 06819033T PL 06819033 T PL06819033 T PL 06819033T PL 1969118 T3 PL1969118 T3 PL 1969118T3
Authority
PL
Poland
Prior art keywords
stem cells
liver
relates
present
progenitor stem
Prior art date
Application number
PL06819033T
Other languages
English (en)
Other versions
PL1969118T5 (pl
Inventor
Etienne Sokal
Mustapha Najimi
Original Assignee
Univ Catholique Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37775557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1969118(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Catholique Louvain filed Critical Univ Catholique Louvain
Publication of PL1969118T3 publication Critical patent/PL1969118T3/pl
Publication of PL1969118T5 publication Critical patent/PL1969118T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
PL06819033T 2005-12-21 2006-12-14 Wyizolowane komórki macierzyste wątroby PL1969118T5 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05447286 2005-12-21
EP2006010014 2006-10-17
PCT/EP2006/012046 WO2007071339A1 (en) 2005-12-21 2006-12-14 Isolated liver stem cells
EP06819033.9A EP1969118B2 (en) 2005-12-21 2006-12-14 Isolated liver stem cells

Publications (2)

Publication Number Publication Date
PL1969118T3 true PL1969118T3 (pl) 2011-07-29
PL1969118T5 PL1969118T5 (pl) 2015-06-30

Family

ID=37775557

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06819033T PL1969118T5 (pl) 2005-12-21 2006-12-14 Wyizolowane komórki macierzyste wątroby
PL10192665T PL2281875T3 (pl) 2005-12-21 2006-12-14 Wyizolowane komórki macierzyste wątroby

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10192665T PL2281875T3 (pl) 2005-12-21 2006-12-14 Wyizolowane komórki macierzyste wątroby

Country Status (13)

Country Link
US (5) US8673635B2 (pl)
EP (2) EP1969118B2 (pl)
JP (1) JP5250423B2 (pl)
CN (1) CN103989710B (pl)
AT (1) ATE498005T1 (pl)
AU (1) AU2006328988B2 (pl)
CA (1) CA2634510C (pl)
DE (1) DE602006020071D1 (pl)
DK (2) DK1969118T4 (pl)
ES (1) ES2672205T3 (pl)
PL (2) PL1969118T5 (pl)
PT (1) PT2281875T (pl)
WO (1) WO2007071339A1 (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1969118T5 (pl) * 2005-12-21 2015-06-30 Univ Catholique Louvain Wyizolowane komórki macierzyste wątroby
US8951792B2 (en) * 2007-07-20 2015-02-10 Cellartis Ab Methods for making definitive endoderm hepatocyte (DE-hep) progenitor cells
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
CA2751332C (en) 2009-02-03 2024-04-02 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
JPWO2011102532A1 (ja) * 2010-02-16 2013-06-17 国立大学法人九州大学 誘導肝細胞
WO2012005690A1 (en) * 2010-07-07 2012-01-12 Massachusetts Institute Of Technology Methods of reconstituting human hepatocytes and human hematopoietic cells in non-human mammals
US8858934B2 (en) * 2010-08-12 2014-10-14 Abag Verwaltungs Gmbh Method for producing cells having characteristics of hepatocytes
PT2667878E (pt) * 2011-01-25 2016-06-03 Univ Catholique Louvain Composições e métodos para o transplante celular
JP6095272B2 (ja) * 2011-03-25 2017-03-15 国立大学法人京都大学 上皮系体性幹細胞の製造方法
ES2600321T3 (es) 2011-08-04 2017-02-08 Ethianum Betriebsgesellschaft Mbh & Co. Kg Medios para la regeneración del hígado
EP2762000A4 (en) 2011-09-30 2015-03-11 Public Univ Corp Yokohama City METHOD OF INDUCING HEPATOCELLULAR VARIATION AND METHOD OF PRODUCING NON-MENTAL CHIMERIC ANIMALS WITH HUMAN LIVER
EP2806879B1 (en) 2012-01-25 2019-03-06 Université Catholique de Louvain Compositions and methods for cell transplantation
US20140162355A1 (en) * 2012-12-07 2014-06-12 Antria, Inc. Formulations Containing and Kit for Using Adipose-Derived Stem Cells and Use Thereof
DK3016665T3 (da) * 2013-07-05 2019-11-25 Univ Catholique Louvain Konditioneret medium fra humane voksne leverstamceller og dets anvendelse i behandlingen af leverlidelser
AU2014314152B2 (en) * 2013-08-28 2020-02-06 Promethera Therapeutics Sa Method for producing adult liver progenitor cells
WO2016001839A1 (en) * 2014-06-30 2016-01-07 Stempeutics Research Pvt. Ltd. Management of liver disease using pooled mesenchymal stromal cells
PL3140393T3 (pl) * 2014-08-28 2023-11-06 Cellaïon SA Sposób wytwarzania komórek progenitorowych dorosłej wątroby
GB2548059B (en) * 2014-11-26 2020-09-02 Accelerated Biosciences Corp Induced hepatocytes and uses thereof
FR3035407B1 (fr) 2015-04-23 2022-06-17 Francais Du Sang Ets Procede de conservation de cellules, tissus ou organes en hypothermie
US10179896B2 (en) 2015-05-12 2019-01-15 Baker Group, LLP Method and system for a bioartificial organ
WO2016181885A1 (ja) * 2015-05-14 2016-11-17 株式会社再生医療推進機構 凍結間葉系細胞の製造方法、及び、移植用治療材の製造方法
CN108431209B (zh) 2015-06-12 2023-02-10 新加坡科技研究局 肝脏干细胞的衍生和成熟肝细胞类型及其用途
US10287543B2 (en) * 2015-11-19 2019-05-14 Miltenyi Biotec, Gmbh Process and device for isolating cells from biological tissue
RU2018128598A (ru) * 2016-01-08 2020-02-11 Кинити Ко., Лтд. Способ продуцирования стволовых клеток/клеток-предшественников печени из зрелых клеток печени с использованием низкомолекулярного соединения
JP6704617B2 (ja) * 2016-01-29 2020-06-03 北海道公立大学法人 札幌医科大学 小型肝細胞の継代培養方法
CA3013630A1 (en) 2016-02-10 2017-08-17 Wake Forest University Health Sciences Model system of liver fibrosis and method of making and using the same
MA45274A (fr) * 2016-03-02 2019-01-09 Univ Catholique Louvain Préparations améliorées de cellules progénitrices hépatiques adultes
JP2019516391A (ja) * 2016-05-24 2019-06-20 リ, アルバートLI, Albert 新規な細胞培養方法、細胞培養システム、およびそれらの使用
WO2018215780A1 (en) 2017-05-24 2018-11-29 Ammun Limited Use of glutamine synthetase for treating hyperammonemia
US11976302B2 (en) 2017-05-06 2024-05-07 Upside Foods, Inc. Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure
WO2019014652A1 (en) * 2017-07-13 2019-01-17 Memphis Meats, Inc. COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF CELL CULTURES USED IN FOOD PRODUCTION
US11407979B2 (en) 2017-09-01 2022-08-09 Colorado State University Research Foundation Intermittent starvation techniques to prolong functional lifetime of liver cells in culture
EP3766529A4 (en) 2018-03-14 2022-03-23 Beacon Medcare (HK) Limited COMPOSITION FOR PURIFICATION OF BIOFLUIDS
CN108823146A (zh) * 2018-06-22 2018-11-16 安徽 一种肝脏干细胞制备和提取方法
CA3122715A1 (en) 2018-12-14 2020-06-18 Promethera Therapeutics Sa Cell composition comprising liver progenitor cells expressing hla-e
WO2020120666A1 (en) 2018-12-14 2020-06-18 Promethera Biosciences S.A./N.V. Liver progenitor cells expressing hla-g, and method for obtaining these cells compositions comprising said cells and their use
CN109735485B (zh) * 2019-01-29 2021-04-16 深圳市拓普生物科技有限公司 人源化肝脏动物模型及其构建方法和应用
TW202100171A (zh) 2019-03-26 2021-01-01 比利時商普羅米修亞生物科技股份有限公司 用於治療非酒精性脂肪肝疾病的成人肝臟前驅細胞
EP3947644A1 (en) 2019-03-26 2022-02-09 Promethera Therapeutics Sa Adult liver progenitor cells for treating acute-on-chronic liver failure
JP7284985B2 (ja) * 2019-03-29 2023-06-01 国立大学法人 長崎大学 肝前駆細胞を含む細胞集団を製造する方法
PT3963050T (pt) * 2019-04-30 2023-11-16 Cellaion Sa Preparação de células progenitoras alogénicas humanas derivadas de fígado
TW202106874A (zh) 2019-04-30 2021-02-16 比利時商普羅米修亞生物科技股份有限公司 人類同種異體肝衍生前驅細胞的製備(一)
EP3966315A1 (en) * 2019-05-09 2022-03-16 FUJIFILM Cellular Dynamics, Inc. Methods for the production of hepatocytes
KR20220035926A (ko) * 2019-07-26 2022-03-22 앰비스 메디신즈 인코포레이티드 간세포 생성을 위한 방법 및 조성물
KR20220081368A (ko) 2019-10-09 2022-06-15 셀라온 에스에이 혈관 과투과성을 특징으로 하는 장애에서 간 전구세포 또는 줄기세포, 이의 용해물 및/또는 조건화 배지의 사용
CN115551994A (zh) 2020-03-11 2022-12-30 倍特博有限公司 产生肝细胞的方法
EP3881853A1 (en) 2020-03-20 2021-09-22 Promethera Therapeutics Sa Human allogeneic liver-derived progenitor cells for use in the treatment of inflammatory and infectious lung diseases and systemic inflammation
EP3929280A1 (en) * 2020-06-26 2021-12-29 Medizinische Hochschule Hannover Process for producing liver cells
WO2023180122A1 (en) 2022-03-24 2023-09-28 Université Catholique de Louvain Use of human allogenic liver-derived progenitor cells for treating and/or preventing cellular senescence

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2917998B2 (ja) * 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
US6069005A (en) 1991-08-07 2000-05-30 Albert Einstein College Of Medicine Of Yeshwa University Hapatoblasts and method of isolating same
PT671923E (pt) 1992-10-09 2001-10-30 Advanced Tissue Sciences Inc Celulas de reserva do figado
US5869243A (en) 1996-03-05 1999-02-09 Rhode Island Hospital Immortalized hepatocytes
CA2266752A1 (en) 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase
US6774120B1 (en) 1999-06-01 2004-08-10 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US8778899B2 (en) 1999-06-01 2014-07-15 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
CN101955906A (zh) * 2000-01-19 2011-01-26 查珀尔希尔-北卡罗莱纳大学 肝脏组织来源
ES2292772T3 (es) 2001-06-22 2008-03-16 Stemcells, Inc. Celulas de injerto de higado, analisis, y sus usos.
US6617152B2 (en) 2001-09-04 2003-09-09 Corning Inc Method for creating a cell growth surface on a polymeric substrate
WO2003033697A1 (en) * 2001-10-18 2003-04-24 Ixion Biotechnology, Inc. Conversion of liver stem and progenitor cells to pancreatic functional cells
JP2006525994A (ja) 2003-05-12 2006-11-16 サラ ファーバー， 非膵島組織における調節された膵ホルモンの産生を誘導する方法
CA2444292A1 (en) 2003-10-03 2005-04-03 Inserm Bipotential liver cell lines from wild-type mammalian liver tissue
JP4749331B2 (ja) * 2003-10-07 2011-08-17 株式会社バイオマスター 脂肪由来前駆細胞の細胞分化
WO2006126219A1 (en) * 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
PL1969118T5 (pl) * 2005-12-21 2015-06-30 Univ Catholique Louvain Wyizolowane komórki macierzyste wątroby

Also Published As

Publication number Publication date
US20140127676A1 (en) 2014-05-08
DK2281875T3 (en) 2018-06-06
AU2006328988A1 (en) 2007-06-28
CA2634510A1 (en) 2007-06-28
JP2009520474A (ja) 2009-05-28
EP2281875A1 (en) 2011-02-09
AU2006328988B2 (en) 2012-08-02
DE602006020071D1 (de) 2011-03-24
EP1969118A1 (en) 2008-09-17
PL1969118T5 (pl) 2015-06-30
US20150306147A1 (en) 2015-10-29
CA2634510C (en) 2018-01-09
US20140286917A1 (en) 2014-09-25
CN103989710A (zh) 2014-08-20
EP1969118B2 (en) 2014-09-10
DK1969118T4 (en) 2014-12-15
WO2007071339A1 (en) 2007-06-28
ES2672205T3 (es) 2018-06-13
JP5250423B2 (ja) 2013-07-31
US9931360B2 (en) 2018-04-03
PT2281875T (pt) 2018-06-11
US20170354687A1 (en) 2017-12-14
US9107910B2 (en) 2015-08-18
EP2281875B1 (en) 2018-03-21
DK1969118T3 (da) 2011-05-16
CN103989710B (zh) 2019-11-15
US8673635B2 (en) 2014-03-18
EP1969118B1 (en) 2011-02-09
ATE498005T1 (de) 2011-02-15
US8778607B2 (en) 2014-07-15
US9775863B2 (en) 2017-10-03
US20080311094A1 (en) 2008-12-18
PL2281875T3 (pl) 2018-08-31

Similar Documents

Publication Publication Date Title
PT2281875T (pt) Células estaminais isoladas do fígado
Hannoun et al. The potential of induced pluripotent stem cell derived hepatocytes
Thorgeirsson et al. Hematopoietic cells as hepatocyte stem cells: a critical review of the evidence
WO2007100692A3 (en) Method of generating human retinal progenitors from embryonic stem cells
PL1888742T3 (pl) Komórki progenitorowe wątroby
EP1857542A4 (en) METHOD FOR IN VITRO AMPLIFICATION OF ADULT STEM CELLS
WO2010017562A3 (en) Induced pluripotent stem cells
WO2011043591A3 (en) Method for differentiation into retinal cells from stem cells
JP2022036183A (ja) 移植のための臓器の改良
WO2009021151A8 (en) Isolation, characterization and propagation of germline stem cells
WO2011043592A3 (en) Compositions for inducing differentiation into retinal cells from retinal progenitor cells or inducing proliferation of retinal cells comprising wnt signaling pathway activators
WO2013124815A3 (en) Mesenchymal stem cells for in vitro modeling and cell-based therapy of human diseases and banks thereof
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
Bilodeau et al. Limitations of recellularized biological scaffolds for human transplantation
WO2007051625A3 (en) Compositions and methods for producing pluripotent cells from adult testis
HK1157814A1 (en) Materials and methods relating to cell based therapies
Deng et al. Hepatic progenitor cell represents a transitioning cell population between liver epithelium and stroma
Maepa et al. Advances in generating liver cells from pluripotent stem cells as a tool for modeling liver diseases
WO2013184193A3 (en) Cancer stem cells and methods of using the same
WO2005094162A3 (en) Culture and use of cells that secrete liver secretory factors
WO2009102366A3 (en) Expression of orphan gpr64 in inflammatory diseases
WO2006105204A3 (en) Compositions and their uses directed to thymus and activation-regulated chemokine (tarc)
Kao et al. Fibronectin suppresses lipopolysaccharide-induced liver damage and promotes the cytoprotection abilities of hepatocyte-like cells derived from human bone marrow mesenchymal stem cells
WO2006121923A3 (en) Cns cells in vitro
GB2458429A (en) Novel mesenchymal progenitor cells derived from human blastocyst-derived stem cells